Dazzi C, Cariello A, Maioli P, Solaini L, Scarpi E, Rosti G, Lanzanova G, Marangolo M
Oncology Department, Ospedale Santa Maria delle Croci, Ravenna, Italy.
Lung Cancer. 1999 May;24(2):81-8. doi: 10.1016/s0169-5002(99)00036-7.
Experimental evidence suggests that tumor growth and progression depend on angiogenesis. In a retrospective study we evaluated the relationship between tumor angiogenesis and survival in patients with NSCLC treated with potentially curative surgery between 1992 and 1997. The study population consisted of 76 patients. An anti-CD34 monoclonal antibody was used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel count (MVC): in each sample the three most intense regions of neovascularization were identified under low microscopic power. A x250 field in each of the three areas was then counted and the highest count of the three fields was recorded. Disease free (DFS) and overall survival (OS) during follow up were evaluated. Gender, age, stage, histologic type and KI-67 were the other factors considered for analysis. The median MVC in our series was 41.5. Among the clinicopathologic parameters examined the microvessel count was the only one to show a significant association with disease free survival in univariate analysis (P = 0.04). MVC value is a new indicator of tumor aggressiveness in patients with NSCLC who underwent potentially curative surgery and should be taken into consideration in selecting patients for adjuvant treatment.
实验证据表明肿瘤的生长和进展依赖于血管生成。在一项回顾性研究中,我们评估了1992年至1997年间接受根治性手术治疗的非小细胞肺癌患者肿瘤血管生成与生存之间的关系。研究人群包括76例患者。使用抗CD34单克隆抗体来测量肿瘤样本中的血管生成。血管生成通过微血管计数(MVC)进行量化:在每个样本中,在低倍显微镜下识别出三个新生血管最密集的区域。然后对这三个区域中的每个区域的一个×250视野进行计数,并记录三个视野中的最高计数。评估随访期间的无病生存期(DFS)和总生存期(OS)。性别、年龄、分期、组织学类型和KI-67是分析时考虑的其他因素。我们系列中的中位MVC为41.5。在检查的临床病理参数中,微血管计数是单因素分析中唯一与无病生存期显示出显著关联的参数(P = 0.04)。MVC值是接受根治性手术的非小细胞肺癌患者肿瘤侵袭性的一个新指标,在选择辅助治疗患者时应予以考虑。